Subsidised Genetic Testing For Hereditary Cancers Starts In December
Starting December 1, subsidised genetic testing for hereditary breast and ovarian cancer will be available at three major specialist outpatient clinics. These include the National Cancer Centre Singapore, the National University Cancer Institute Singapore, and Tan Tock Seng Hospital. This initiative is designed to make early detection more accessible, allowing individuals to identify genetic mutations that significantly increase the likelihood of developing these specific types of cancer.
Financial support for the testing is structured to reduce the burden on patients. Eligible citizens and permanent residents can access means-tested subsidies of up to 70 percent. For those with sufficient balances, MediSave accounts can be used to fully offset the remaining costs of the test, which typically costs around 1,000 dollars before any subsidies are applied. Additional support is also available for seniors from the Pioneer and Merdeka Generations.
Target Groups For Genetic Screening
The testing is open to any eligible individual regardless of gender, as genetic mutations can be passed to both males and females. Medical professionals recommend the test for three primary groups. First, it is advised for patients already diagnosed with breast or ovarian cancer who exhibit hereditary risk factors. Second, first-degree relatives of known gene variant carriers are encouraged to undergo screening to determine their own status.
Third, the test is recommended for individuals with a strong family history of these cancers, particularly when the affected relatives are unavailable for testing. This process of screening family members after a positive result is known as cascade testing, and it is also eligible for MediSave coverage. It is estimated that approximately 2,000 people per year will benefit from these subsidised testing services.
Understanding The Risks And Prevention
Genetic mutations linked to hereditary breast and ovarian cancer are present in about one out of every 150 people in the region. For females, carrying such a mutation can increase the lifetime risk of developing these cancers by five to ten times compared to the general population. Early identification through genetic testing allows patients to pursue preventive medical interventions that can drastically lower these risks.
Financial assistance extends beyond the initial test to include downstream medical care. Risk-reducing breast removal surgery, which can lower cancer risk by at least 90 percent, is currently covered by MediSave and MediShield Life. By the end of 2026, similar coverage will be extended to the removal of fallopian tubes and ovaries, a procedure that reduces ovarian cancer risk by more than 80 percent.
Long Term Surveillance And Medication
For those who choose surveillance over surgery, annual scans such as mammograms and breast MRIs can be funded through specific MediSave limits. The Outpatient Scans limit provides up to 600 dollars annually, while seniors aged 60 and above can access an additional 400 dollars per year through their Flexi-MediSave accounts. This ensures that high-risk individuals can maintain regular monitoring without facing prohibitive costs.
Preventative drug therapies also remain accessible. Endocrine treatments and oral contraceptives continue to receive subsidies provided they are listed under the Medication Assistance Fund and the Standard Drug List. By integrating affordable testing with comprehensive follow-up care, the healthcare system aims to reduce the overall burden of hereditary cancers on families and the broader medical infrastructure through timely intervention.
The financial framework for these screenings is designed to evolve alongside patient needs. While current MediSave limits are being utilized to cover the genetic tests, a more enhanced version of the existing MediSave500/700 system is scheduled to take effect on January 1, 2027. This upcoming Chronic and Preventive Care scheme will further refine how costs are offset, ensuring that preventive measures remain sustainable for the population over the long term.
In the interim, the current system ensures that no eligible person is left without options. Seniors aged 60 and above are specifically encouraged to utilize their Flexi-MediSave accounts to defray any remaining out-of-pocket expenses that subsidies may not cover. By strengthening these financial measures, the goal is to ensure that a wider range of individuals can benefit from early detection and timely medical interventions in the coming years.